Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Novel strategies to evaluate biomarkers of interest in multiple myeloma

Francesco Maura • 12 Dec 2022
ASH 2022
Multiple Myeloma

In this video, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, outlines the importance of integrating novel biomarkers in multiple myeloma (MM) research, and further comments on novel models and strategies being used in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Maura

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
3:43
Genomic profiling to predict prognosis for patients with HR-SMM
Francesco Maura • 8 Dec 2023
1:15
Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Francesco Maura • 8 Dec 2023
2:08
Novel genomic alterations driving tumor suppressor gene inactivation in multiple myeloma
Francesco Maura • 8 Dec 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals